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Abstract
Objective: The objective of our study was to assess meningococcal ACWY (MenACWY) vaccine uptake among men who
have sex with men (MSM) during an ongoing, invasive meningococcal disease outbreak in Southern California. This research
was important to inform future vaccination uptake interventions for this high-priority population.
Methods: We conducted venue-based sampling to recruit and enroll MSM living in Los Angeles County, California, from
December 2016 through February 2017. We conducted bivariate and multivariable analyses to evaluate associations between
MenACWY vaccine uptake and other predetermined factors.
Results: Of 368 participants, 138 (37.5%) reported receiving the MenACWY vaccine. In multivariable analyses, older age
(adjusted odds ratio [aOR] ¼ 2.57; 95% confidence interval [CI], 1.31-5.03), previous diagnosis of a sexually transmitted
infection (aOR ¼ 2.22; 95% CI, 1.14-4.30), belief that MenACWY vaccine is important (aOR ¼ 3.49; 95% CI, 1.79-6.82),
confidence in the MenACWY vaccine (aOR ¼ 5.53; 95% CI, 3.11-9.83), and knowing someone who had been vaccinated (aOR
¼ 5.82; 95% CI, 3.05-11.12) were significantly associated with MenACWY vaccine uptake.
Conclusions: Our findings reflect low uptake of the recommended MenACWY vaccine among MSM after a local
outbreak, despite public health efforts. In addition to ongoing, widespread campaigns to inform MSM about local
outbreaks and vaccination recommendations, MSM may be responsive to direct outreach from peers who have been
vaccinated.
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Reports of invasive meningococcal disease (IMD) out-
breaks in the United States and worldwide have been pub-
lished since the mid-1990s,1-3 including outbreaks in
communities of men who have sex with men (MSM).4
IMD is characterized by a sudden clinical onset of high
fever, headache, nausea, vomiting, rash, stiff neck, and
confusion that can lead to meningococcal meningitis and/or
meningococcal septicemia. If not treated, these infections
can be deadly in a matter of hours. The mortality rate of
IMD is high (approximately 10%-30% of people infected
with IMD die), and IMD can result in loss of limbs, loss of
hearing, and damage to the central nervous system and
kidneys.5,6
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From March 2016 through July 2017, an outbreak of 31
cases of IMD, primarily among MSM, occurred in Southern
California.7,8 Five of the 31 cases were people living with
HIV/AIDS (PLWHA).7 In response to this outbreak, the
California Department of Public Health issued a health advi-
sory in August 2016 recommending 2 doses of meningococ-
cal ACWY (MenACWY) vaccine for adult PLWHA and 1
dose of MenACWY vaccine for all MSM not living with
HIV/AIDS in Southern California.9 This recommendation
was a change from a previous MenACWY vaccination rec-
ommendation for MSM, which applied to MSM who had
close or intimate contact with multiple partners or sought
partners through the use of social networking applications,
particularly MSM who shared cigarettes or marijuana, or
used illegal drugs.10
At a meeting in June 2016, the Advisory Committee on
Immunization Practices (ACIP) recommended a 2-dose pri-
mary series of the MenACWY vaccine, with doses 2 months
apart, followed by a booster vaccine every 5 years for all
HIV-infected people aged 2 months.11-13 This recommen-
dation was published in Morbidity and Mortality Weekly
Report in November 2016.11 Despite wide dissemination of
updated recommendations, health care providers attending to
PLWHA may not have been knowledgeable about them.14,15
Differences in adult immunization recommendations accord-
ing to certain patient demographic characteristics (eg, age,
comorbidities) and confusion about contraindications and
precautions may also have created informational barriers for
health care providers.16-18 In addition to the challenges of
keeping abreast of immunization recommendations, not all
providers use recommended immunization schedules. In one
survey, only 60% of physicians and 56% of physician assis-
tants, nurse practitioners, and registered nurses reported
using official guidelines as their source of information about
adult immunizations.19 Informational barriers also impede
patient receipt of immunizations; the rate of receipt for the
second dose of the MenACWY vaccine was low (26.6%)
among PLWHA as of December 2015,20 possibly because
of a lack of awareness about the necessity of a second dose or
the misperception that CD4 counts will decrease and viral
loads will increase after vaccination.21,22
Delays in reporting, low participation rates among adults,
limited sociodemographic information, and incomplete data
in state immunization registries make it difficult to discern
rates of MenACWY vaccine coverage among MSM.23,24
Fewer than half of adults in California have 1 or more vac-
cination records in the California Immunization Registry, a
centralized state registry of vaccination records submitted by
vaccination service providers (eg, physicians, pharmacists),
and sexual orientation data are not collected for people who
are included.23 Few surveys assessing vaccination coverage
among MSM have been conducted in California, and none
attempted to quantify coverage beyond a specific vaccine
type or limited geographic region.18,25-27 Therefore, compre-
hensive vaccination coverage among MSM in Southern
California is not known. The objective of our study was to
describe MenACWY vaccine uptake amongMSM, including
MSM living with HIV, in Los Angeles County, California.
This information could help to detect potential gaps in uptake
that could result in an underimmunized cluster in Los
Angeles County and identify factors associated with
underimmunization.28
Methods
Theoretical Framework
To examine factors that may contribute to MenACWY vac-
cine uptake among MSM, we used a socioecological frame-
work for empirical investigation of multiple levels of
influence.29 From a conceptual standpoint, immunization
decision making is informed by a series of events driven
by an entire ecological system, which includes direct and
indirect influencers. This model specifies 3 levels of beha-
vioral dynamics: individual, social/contextual, and struc-
tural. The individual level refers to factors, such as
perception of disease vulnerability, that are specific to the
individual. The social/contextual level involves immuniza-
tion decision-making support from peers and other people
with whom an individual has a socially close relationship.
Interactions at this level are theorized to have a strong effect
on an individual’s health decision making because of social
network dynamics. The structural level represents policies
and recommendations affecting MSM’s health interests
locally (eg, local or regional recommendations for meningo-
coccal immunization in the context of an outbreak).29 By
identifying influences on the MenACWY vaccination beha-
vior of MSM, we sought to uncover the socioecological fac-
tors that could be shaped into useful vaccine promotion
interventions for MSM in Southern California.
Study Design and Sample
From December 2016 through February 2017 (the study
period), we executed a rapid-response venue-based sampling
strategy to gather survey data from MSM in selected venues
in Los Angeles County. This method has been successful in
obtaining similar representative samples in serial cross-
sectional studies, such as the National HIV Behavioral
Surveillance survey.30,31 Our venue sample included 146
locations, including clinics, community-based organizations,
AIDS service organizations, specialized businesses serving
the LGBTQ (lesbian, gay, bisexual, transgender, queer/ques-
tioning) community, bathhouses, stores, bars, clubs, recrea-
tional areas and facilities, and restaurants and coffee shops.
We developed this list based on previous work by the first
author (I.W.H.) with MSM in Los Angeles County and gui-
dance from a standing community advisory board consisting
of representatives from the community-based agencies with
whom the Southern California HIV/AIDS Policy Research
Centers collaborate. We collected data in 4-hour blocks in
the morning and early afternoon (10 AM-2 PM), late afternoon
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(2 PM-6 PM), evening (6 PM-10 PM), and late night (10 PM-
2 AM). Before each 4-hour data-collection event, we selected
3 venues at random from the sampling frame of 146
venues. We instructed data collectors to approach male
patrons entering or exiting the venue to recruit participants
for the study survey.
Recruiters asked a brief series of 7 standardized questions
to men who expressed interest in the survey and recorded
responses on an iPad to assess their eligibility. Men were
eligible to enroll if they met the following criteria: (1) were
aged 18, (2) were assigned male sex at birth, (3) identified
as male, (4) reported having sex with men in the past
3 months, (5) resided in Los Angeles County, (6) spoke
English or Spanish, and (7) were able to provide informed
consent. Eligible participants were invited to take a 15- to
30-minute survey (mean, 17.7 minutes), which was conducted
by trained interviewers on iPads outside of the venue. Partici-
pants received a $50 cash incentive for participating. The
UCLA North General Institutional Review Board reviewed
and approved the study before survey implementation.
Survey Instrument and Measurement
We developed the consent form, the series of questions for
assessing participant eligibility, and the survey instrument in
English and Spanish by using forward-backward translation.
The Flesch Reading Ease scale (62.9) and Flesch-Kincaid
grade (7.1) were acceptable, corresponding to a sixth- to
eighth-grade level.32 The readability of materials was in the
standard range (between “fairly easy” and “fairly difficult”)
according to the Flesch Readability Chart.33 To assess vac-
cination status, we asked respondents, “Quadrivalent menin-
gococcal vaccination is a vaccination that protects against 4
types of meningitis; have you received quadrivalent menin-
gococcal vaccination?” Participants could respond yes, no,
or “not sure.” Our analysis included participants who
responded yes or no to this item and excluded those who
responded “not sure.”
We collected data on sociodemographic characteristics,
including age (18-29, 30), race/ethnicity (non-Hispanic
white, non-Hispanic black/African American, Hispanic, and
other), health insurance (yes/no), highest level of education
completed (high school diploma,some college), employ-
ment status (employed full time, other), and annual house-
hold income (<$20000, $20000). To classify participants
by race/ethnicity, we first asked about ethnicity (Hispanic or
non-Hispanic) and then asked about race using US Census
categories (non-Hispanic white, non-Hispanic black/African
American, Hispanic, and other, which included American
Indian/Alaska Native, Asian American, and Native Hawaiian
or Other Pacific Islander).
We also collected data on individual risk and protective
factors, including data on marijuana use, illicit substance use
(eg, cocaine, amphetamines, opiates, prescription drugs
without a physician’s permission), sexual behavior (eg, con-
domless anal sex), HIV status, diagnoses of sexually
transmitted infections (STIs), and multivitamin use. The
questionnaire also included items designed to measure psy-
chosocial indicators of attitudes and perceptions about
immunization decision making. One item asked partici-
pants to indicate whether MenACWY vaccination was
important to them (yes/no), and another asked if partici-
pants knew anyone who had received MenACWY vaccina-
tion (yes/no).
The survey assessed the following 3 psychosocial cate-
gories on a 5-point Likert scale (1 ¼ strongly disagree to
5 ¼ strongly agree)34: (1) barriers to receiving the
MenACWY vaccine (6 items), (2) perceived susceptibility
of acquiring meningococcal disease (4 items), and (3) per-
ceived benefits of MenACWY vaccination (4 items). Items
assessing barriers to receiving the MenACWY vaccine
included “I don’t have time to get vaccinated.” Items asses-
sing perceived meningococcal disease susceptibility
included “I am not at risk for getting infected with meningo-
coccal disease” (reverse coded). Items assessing perceived
benefits of MenACWY vaccination included “Getting vacci-
nated against meningococcal disease would be a good way to
protect the health of my sex partner(s).” We also assessed
participants’ confidence in the safety and efficacy of the
MenACWY vaccine. We averaged the ratings of items in
each category to create raw summary scores.
At the social/contextual level, we assessed the extent of
participant engagement in social media and the number of
platforms they were active on, with items such as “How often
do you use social networking websites like Facebook, Twit-
ter, Pinterest, or Instagram?” and “How many Twitter fol-
lowers do you have?” In addition, we assessed the social
norms and social influence of vaccination behavior. The
social norms category included items such as “Most people
I know are being vaccinated.” The social influence category
included 5 items such as “I often persuade others to get
vaccinated.” We measured the previously mentioned items
by using a 5-point Likert scale (1 ¼ strongly disagree to 5 ¼
strongly agree).34
At the structural level, to account for meningococcal dis-
ease awareness campaigns that had occurred in Hollywood
and West Hollywood, we used participants’ ZIP codes to
determine residence in these targeted areas. We assessed
neighborhood-level poverty by whether a participant lived
in a ZIP code where 20% of all families lived below the
federal poverty level.35
Statistical Analysis
We evaluated characteristic differences between men who
reported having received the MenACWY vaccine and men
who reported not receiving the vaccine by using cross-
tabulations and descriptive analyses in SAS/STAT version
9.3.36 We conducted an exploratory factor analysis to iden-
tify factors associated with immunization decisions and
assessed the internal consistency of each factor. We averaged
the ratings of items that were measured on a 5-point Likert
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scale to create raw summary scores for each category. We
determined that a Cronbach a reliability estimate of 0.60
would support the reliability of each factor associated with
MenACWY vaccine uptake.37 We conducted bivariate and
multivariable correlations to assess associations between
individual, social/contextual, and structural factors and
MenACWY vaccine uptake. We used Pearson w2 tests and
Wilcoxon signed-rank tests to analyze associations between
sets of the outcome variable and socioecological factors. We
set significance at a¼ .10 for the bivariate level because this
step was exploratory; in the multivariable models, we set
significance at a  .05. We entered significant correlates
of MenACWY vaccination at the bivariate level and vari-
ables consistent with our conceptual framework into a multi-
variable model predicting MenACWY vaccination. The
multivariable logistic regression analysis evaluated the asso-
ciation between independent variables and the dependent
variable (ie, MenACWY vaccination) while adjusting for
covariates.
Results
We approached approximately 2250 men to participate in the
study. Our overall response rate was 69.4% (520 eligible
respondents of 749 screened). Of these 520 participants,
368 responded yes or no to the question assessing
MenACWY vaccination, and 152 were not sure about
whether they had received the vaccine and were excluded
from further analysis.
Participants were young (mean [standard deviation (SD)],
34.2 [10.4] years) and racially/ethnically diverse. Of the 368
participants, 127 (34.5%) identified as non-Hispanic white,
51 (13.9%) as non-Hispanic black/African American, 130
(35.3%) as Hispanic, and 60 (16.3%) as other (Table 1). Of
the 368 participants, 187 (50.8%) were college educated, 72
(19.6%) made <$20000 annually, 321 (87.2%) had health
insurance, 156 (42.4%) resided in either Hollywood or West
Hollywood, and 113 (30.7%) lived in areas where 20% of
all families lived below the federal poverty level. Of the 368
participants, 331 (89.9%) reported sex with men only; 101
(27.5%) reported 6 sexual partners in the previous 6
months, 186 (50.5%) reported condomless anal sex in the
previous 6 months, and 47 (12.8%) were HIV-positive.
Among the 368 participants, only 138 (37.5%) reported
receiving the MenACWY vaccine. Among the 47 HIV-
positive participants, 23 (48.9%) reported receiving the vac-
cine; of the 23 HIV-positive MSM who had been vaccinated,
19 (82.6%) reported receiving the vaccine in the previous
6 months. However, only 16 of the 23 (69.6%) HIV-
positive participants who had been vaccinated reported com-
pleting the recommended 2-dose schedule, or 34.0% of all 47
HIV-positive MSM in our sample. Among the 318 HIV-
negative participants, 115 (36.2%) reported receiving the
MenACWY vaccine; of the 115 HIV-negative participants
who had been vaccinated, 59 (51.3%) reported being vacci-
nated within the previous 6 months.
Bivariate and Multivariable Results
Compared with the percentage of participants who reported
not receiving the MenACWY vaccine (106/230, 46.1%), a
greater percentage (81/138, 58.7%) of participants who
reported receiving the vaccine had some college or more
(P ¼ .02) (Table 1). Compared with fewer than half
(92/230, 40.0%) of those who reported not receiving the
MenACWY vaccination, more than half (77/138, 55.8%)
of participants who reported receiving the vaccine had been
diagnosed with an STI (P ¼ .003).
In the bivariate analysis of perceived facilitators and bar-
riers to vaccination, participants who reported receiving the
MenACWY vaccine had significantly lower scores (mean
[SD] score ¼ 2.0 [0.7]) on the items assessing barriers to
receiving the vaccine compared with those who reported
not receiving the vaccine (mean [SD] score ¼ 2.2 [0.7])
(P < .001) (Table 2). Participants who reported receiving
the MenACWY vaccine had significantly higher scores
(mean [SD] score ¼ 3.6 [0.9]) on the items assessing
susceptibility to meningococcal disease (P ¼ .004) than
participants who reported not receiving the vaccine (mean
[SD] score ¼ 3.4 [0.8]).
In our multivariable model, age 30 (adjusted odds ratio
[aOR] ¼ 2.57; 95% confidence interval [CI], 1.31-5.03), a
diagnosis of an STI (aOR¼ 2.22; 95% CI, 1.14-4.30), know-
ing anyone who had received the MenACWY vaccine (aOR
¼ 5.82; 95% CI, 3.05-11.12), believing MenACWY vacci-
nation was important (aOR ¼ 3.49; 95% CI, 1.79-6.82), and
having confidence in the MenACWY vaccine (aOR ¼ 5.53;
95% CI, 3.11-9.83) were significantly associated with
MenACWY vaccine uptake (Table 3).
Discussion
Our study is among the first to examine MenACWY vacci-
nation coverage in a sample of MSM in Southern California
during an IMD outbreak. Despite recommendations by the
California Department of Public Health and the Los Angeles
County Department of Public Health, vaccination in
response to this outbreak among HIV-negative and HIV-
positive MSM in our sample was low. Currently, data on
sexual practices or sexual orientation are not linked with data
on vaccination in immunization registries, making our work
especially important for understanding MenACWY vaccina-
tion coverage among MSM.38,39 Recent IMD outbreaks have
primarily affected MSM in Chicago, New York, Toronto,
and Miami; coordinated efforts to improve immunization
surveillance among MSM will enable better tracking of
MenACWY vaccine uptake to assess local immunization
rates across the country.8,39,40
In accordance with our theoretical framework, we identi-
fied several individual-level factors associated with reported
receipt of the MenACWY vaccine. We found that older age
was associated with greater MenACWY vaccine uptake.
This finding is consistent with findings from other studies
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Table 1. Reported receipt of meningococcal ACWY vaccine among a sample of men who have sex with men (MSM) (N ¼ 368), by
socioecological characteristics, Los Angeles County, California, 2016-2017a
Characteristicsb
Reported Receipt of Vaccine,
No. (%)c
P ValuedYes No Total
Total 138 (37.5) 230 (62.5) 368 —
Sociodemographic factors
Age, y
18-29 60 (43.5) 94 (40.9) 154 (41.8) .62
30 78 (56.5) 136 (59.1) 214 (58.2)
Race/ethnicity
Non-Hispanic white 53 (38.4) 74 (32.2) 127 (34.5) .05
Non-Hispanic black/African American 20 (14.5) 31 (13.5) 51 (13.9)
Hispanic 52 (37.7) 78 (33.9) 130 (35.3)
Othere 13 (9.4) 47 (20.4) 60 (16.3)
Sexual behavior
Men only 128 (92.8) 203 (88.3) 331 (89.9) .17
Men and women 10 (7.2) 27 (11.7) 37 (10.1)
Education
High school diploma 57 (41.3) 124 (53.9) 181 (49.2) .02
Some college 81 (58.7) 106 (46.1) 187 (50.8)
Employmentc,f
Employed full-time 92 (66.7) 134 (58.3) 226 (61.4) .13
Other 46 (33.3) 94 (40.9) 140 (38.0)
Annual household income, $c
<20000 20 (14.5) 52 (22.6) 72 (19.6) .05
20000 117 (84.8) 173 (75.2) 290 (78.8)
Insurancec
Yes 127 (92.0) 194 (84.3) 321 (87.2) .11
No 11 (8.0) 30 (13.0) 41 (11.1)
Individual risk and protective factors
Uses marijuana 70 (50.7) 119 (51.7) 189 (51.4) .85
Uses illicit substancesg 73 (52.9) 98 (42.6) 171 (46.5) .06
Has a sexually transmitted infectionh 77 (55.8) 92 (40.0) 169 (45.9) .003
No. of men had sex with in previous 6 monthsc
0-5 90 (65.2) 175 (76.1) 265 (72.0) .07
6-10 22 (15.9) 32 (13.9) 54 (14.7)
11 24 (17.4) 23 (10.0) 47 (12.8)
Has had any receptive condomless anal sex in previous 6 monthsc 81 (58.7) 105 (45.7) 186 (50.5) .01
HIV statusc
HIV positive 23 (16.7) 24 (10.4) 47 (12.8) .09
HIV negative 115 (83.3) 203 (88.3) 318 (86.4)
Takes a multivitamin 83 (60.1) 108 (47.0) 191 (51.9) .01
Social and contextual factors
Knows anyone who received meningococcal ACWY vaccinec 91 (65.9) 47 (20.4) 138 (37.5) <.001
Believes that receiving meningococcal ACWY vaccine is important 112 (81.2) 102 (44.3) 214 (58.2) <.001
Structural factors
Resides in Hollywood or West Hollywood 61 (44.2) 95 (41.3) 156 (42.4) .59
Resides in a ZIP code where 20% of all families live below the federal poverty level 36 (26.1) 77 (33.5) 113 (30.7) .14
aStudy participants completed a questionnaire designed to examine factors associated with uptake of meningococcal ACWY vaccine among MSM during an
outbreak of invasive meningococcal disease in Southern California. The questionnaire was administered by using a venue-based sampling strategy, and all data
were self-reported.
bData were missing on study participants for the following variables: 2, employment; 6, annual household income; 6, insurance; 2, no. of men had sex with in
previous 6 months; 1, has had any receptive condomless anal sex in previous 6 months; 3, HIV status; 4, knows anyone who received meningococcal ACWY
vaccine.
cPercentages are based on the number of study participants indicated in the column head. Some participants did not answer all questions; thus, some
categories may not add to column total or 100%.
dP values determined by Pearson w2 test; a level set at .05.
eOther race/ethnicity includes American Indian/Alaska Native, Asian American, and Native Hawaiian or Other Pacific Islander.
fParticipants were categorized as “other” if they chose an option other than “employed full-time” when asked, “Which of the following best describes your
current employment status?” Other response options included employed part-time, student, military, unemployed and looking for work, unemployed and not
looking for work, unable to work, retired, and other.
gIllicit substances included cocaine, amphetamines, opiates, and prescription medications without a physician’s permission.
hParticipants were asked, “Have you ever had any of the following sexually transmitted diseases?” Possible responses were yes, no, or “don’t know” to each of
the following: gonorrhea (ie, “drip,” “clap”), syphilis, chlamydia, genital or rectal warts, genital or rectal herpes, and any other sexually transmitted disease
(besides HIV).
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that showed older MSM (aged 26) tended to have higher
uptake of health-promoting behaviors, such as HIV testing41
and pre-exposure prophylaxis,42 than younger MSM (aged
25). Given recommended meningitis vaccination sche-
dules, it is surprising that older age was associated with
greater vaccination uptake. ACIP recommends MenACWY
vaccination for all adolescents aged 11-18, with vaccination
occurring at age 11 or 12 and a booster at age 16.43 Another
study reported increases in 1 MenACWY vaccine dose
among boys and girls aged 13-17, from 76.6% in 2013 to
79.3% in 2014,44 whereas the overall uptake among men
aged 18-29 in our sample was 43.5%. Gay and bisexual
adolescents may be more willing to adhere to vaccination
guidelines as they roll out, given that many of them are
included in groups for which MenACWY vaccination is rec-
ommended: first-year college students living in residence
halls and military recruits.45
Compared with MSM who reported not receiving the
MenACWY vaccine, MSM who reported receiving the
MenACWY vaccine were more likely to have a diagnosis
of an STI. Other studies have found that recent diagnosis of
an STI is a risk factor for meningococcal disease.46 This
finding, along with greater percentages of MenACWY vac-
cine uptake among MSM reporting receptive condomless
anal sex (although not significant), suggests that those most
at risk for meningitis may be more likely to be reached by
IMD prevention messaging. Health providers who see MSM
for STI treatment may be attuned to their susceptibility for
other infectious diseases, including IMD, and prompt vacci-
nation.47,48 Future interventions to increase MenACWY vac-
cine uptake among MSM during outbreaks could ask STI
clinics to disseminate vaccines to MSM.
Participants who reported receiving the MenACWY vac-
cine had a higher prevalence of HIV than did participants
who reported not receiving the vaccine. However, this dif-
ference was not significant in our multivariable analysis. Of
23 HIV-positive MSM who received 1 dose of the
MenACWY vaccine, 16 (70%) received a second dose. Thus,
only 34% (16/47) of HIV-positive MSM in our sample had
followed the 2016 ACIP recommendation of 2 MenACWY
vaccine doses at the time of our survey.11 However, some of
these participants might not have been candidates for the
second dose because the recommended interval between
doses is 2 months. Interestingly, 83% (19/23) of vaccinated
HIV-positive MSM (compared with 53% [59/115] of vacci-
nated HIV-negative MSM) had been vaccinated in the pre-
vious 6 months. The high percentage of HIV-positive
participants who had been vaccinated in the previous 6
Table 2. Perceived barriers and facilitators to receiving meningococcal ACWY vaccine among a sample of men who have sex with men
(MSM) (N ¼ 368), by whether or not the study participant reported receiving the vaccine, Los Angeles County, California, 2016-2017a
Barriers and Facilitators Cronbach b
Raw Summary Scorec
P Valued
Reported
Receiving Vaccine
Reported Not
Receiving Vaccine All
General vaccination barrierse 0.68 2.0 (0.7) 2.2 (0.7) 2.1 (0.7) <.001
General vaccination facilitatorsf 0.87 4.3 (0.9) 4.1 (0.9) 4.1 (0.9) <.001
General vaccination confidenceg 0.88 4.1 (0.6) 3.7 (0.7) 3.8 (0.7) <.001
Medical provider trusth 0.79 4.3 (0.6) 4.0 (0.6) 4.1 (0.6) <.001
Social normsi 0.65 4.1 (0.7) 3.8 (0.7) 3.9 (0.7) <.001
Social influencej 0.70 3.4 (0.7) 2.9 (0.7) 3.1 (0.8) <.001
MenACWY vaccine confidencek 0.62 4.0 (0.7) 3.2 (0.6) 3.5 (0.7) <.001
Meningitis susceptibilityl 0.70 3.6 (0.9) 3.4 (0.8) 3.5 (0.8) .004
Meningitis vaccine facilitatorsm 0.84 4.3 (0.7) 3.9 (0.7) 4.1 (0.7) <.001
Meningitis severityn 0.74 4.6 (0.8) 4.6 (0.7) 4.6 (0.7) .62
Abbreviation: MenACWY, meningococcal ACWY.
aStudy participants completed a questionnaire designed to examine factors associated with uptake of MenACWY vaccine among MSM during an outbreak of
invasive meningococcal disease in Southern California. The questionnaire was administered by using a venue-based sampling strategy, and all data were self-
reported.
bA Cronbach a reliability estimate of .60 was determined to support the reliability of each factor associated with vaccine uptake of MenACWY vaccine.
cAll items were measured on a 5-point Likert scale (1¼ strongly disagree to 5¼ strongly agree); ratings were averaged to create raw summary scores for each
category.
dWilcoxon signed-rank tests were used because data were not distributed normally; a level set at <.05.
eItems assessed participant’s perception that given factors are barriers to vaccination.
fItems assessed participant’s perception that vaccination is beneficial.
gItems assessed participant’s confidence in the safety and efficacy of vaccines for MSM.
hItems assessed participant’s trust in his medical provider.
iItems assessed participant’s perception about peers’ behavior and attitudes with regard to vaccination.
jItems assessed how participant is influenced by peers’ behavior and attitudes with regard to vaccination.
kItems assessed participant’s confidence in the safety and efficacy of the MenACWY vaccine.
lItems assessed participant’s perception that he is susceptible to acquiring invasive meningococcal disease.
mItems assessed participant’s perception that meningococcal vaccination is beneficial.
nItems assessed participant’s perception that meningococcal disease is a serious illness that can result in negative health outcomes.
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Table 3.Multivariable logistic model investigating factors associated with the receipt of meningococcal ACWY (MenACWY) vaccine among
a sample of men who have sex with men (MSM) (N ¼ 350), Los Angeles County, California, 2016-2017a
Characteristic Adjusted Odds Ratiob (95% CI) P Valuec
Age, y
18-29 1 [Reference]
30 2.57 (1.31-5.03) .006
Race/ethnicity
Non-Hispanic white 1 [Reference]
Non-Hispanic black/African American 1.30 (0.51-3.36) .42
Hispanic 1.53 (0.69-3.38) .11
Otherd 0.51 (0.18 -1.45) .06
Education
High school diploma 1 [Reference]
Some college 0.91 (0.48 -1.74) .77
Annual household income, $
<20000 1 [Reference]
20000 0.77 (0.33 -1.80) .54
Resides in Hollywood or West Hollywood
No 1 [Reference]
Yes 1.29 (0.67-2.49) .44
Resides in a ZIP code where 20% of all families are living
below the federal poverty level
No 1 [Reference]
Yes 0.97 (0.48 -1.93) .93
Illicit drug usee
No 1 [Reference]
Yes 1.21 (0.65-2.24) .56
Has any sexually transmitted infection
No 1 [Reference]
Yes 2.22 (1.14-4.30) .02
No. of men had sex with in previous 6 months
0-5 1 [Reference]
6-10 0.57 (0.24 -1.38) .33
11 0.80 (0.32-2.01) .91
Receptive condomless anal sex in previous 6 months
No 1 [Reference]
Yes 1.83 (0.99-3.38) .05
HIV status
Negative 1 [Reference]
Positive 1.12 (0.43-2.91) .81
Takes a multivitamin
No 1 [Reference]
Yes 1.76 (0.95-3.26) .07
Knows anyone who received MenACWY vaccine
No 1 [Reference]
Yes 5.82 (3.05-11.12) <.001
Belief in importance of MenACWY vaccine
Not important 1 [Reference]
Important 3.49 (1.79-6.82) <.001
MenACWY vaccine confidencef 5.53 (3.11-9.83) <.001
Meningitis susceptibilityg 0.84 (0.57 -1.23) .37
Meningitis vaccine facilitatorsh 0.91 (0.56 -1.48) .70
aStudy participants completed a questionnaire designed to examine factors associated with uptake of MenACWY vaccine among MSM during an outbreak of
invasive meningococcal disease in Southern California. The questionnaire was administered by using a venue-based sampling strategy, and all data were self-
reported. Eighteen participants were excluded from the multivariable analysis because of missing data.
bAdjusting for all variables in the table.
cP values determined by multivariable logistic regression; a level set at .05.
dOther race/ethnicity includes American Indian/Alaska Native, Asian American, and Native Hawaiian or Other Pacific Islander.
eIllicit drugs included cocaine, amphetamines, opiates, and prescription medications without a physician’s permission.
fItems assessed participant’s confidence in the safety and efficacy of the MenACWY vaccine.
gItems assessed participant’s perception that he is susceptible to acquiring invasive meningococcal disease.
hItems assessed participant’s perception that meningococcal vaccination is beneficial.
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months suggests that PLWHA may be adhering to the 2016
ACIP recommendations targeting PLWHA. However, much
work remains to be done to educate providers and patients,
including disseminating comprehensive information about
IMD, MenACWY vaccination, and appropriate dosing sche-
dules.39 This work is especially important for HIV-positive
MSM, for whom 2 doses are required to achieve maximum
vaccine efficacy.
MSM’s perceived susceptibility of acquiring meningo-
coccal disease, belief in the importance of the MenACWY
vaccine, and confidence in the MenACWY vaccine were
associated with MenACWY vaccine uptake. These findings
are in line with theoretical models of health behavior that
emphasize susceptibility to disease as a key driver of beha-
vior.49 Public health education efforts may be enhanced by
messages that emphasize personal health risks, the safety and
efficacy of the MenACWY vaccine, and the importance of
meningococcal vaccines for men’s health in jurisdictions
with IMD outbreaks. During IMD outbreaks, public health
practitioners must be especially attuned to these individual-
level factors. During the 2012 Los Angeles IMD outbreak,
high-risk MSM (ie, those who have close/intimate contact
with multiple partners, those who visit bars or clubs, and
those who smoke or use illegal drugs) were recommended
to receive the vaccine.6 During the 2016-2017 outbreak, the
recommendation was broadened to all MSM, regardless of
risk behaviors.9 Although high-risk MSM have had years to
respond to recommendations, MSM who do not engage in
high-risk behaviors may hesitate to get vaccinated because of
the recency of the recommendation change. Social marketing
campaigns that emphasize vaccine recommendations in the
context of an outbreak, along with additional information on
individual risk assessment, may be useful.
In our multivariable model, the strongest predictor of
MenACWY vaccine uptake was knowing anyone who had
received the MenACWY vaccine. Health risk and protective
behaviors tend to cluster within networks.50 Because our data
were cross-sectional, we could not determine the processes
of selection and influence. It is conceivable that similar val-
ues on immunization and health behavior among peers made
participants who had received the MenACWY vaccine more
likely than participants who had not received the vaccine to
know someone who had been vaccinated. It is also concei-
vable that people who get vaccinated and tell their friends
cause greater MenACWY vaccine uptake in their networks.
In Los Angeles County, outbreak messaging relied on social
marketing strategies (eg, outdoor advertising) and advisories
issued by LGBTQ-specific health care providers. Our find-
ings indicated that network-based interventions may be par-
ticularly effective in increasing MenACWY vaccine uptake
among MSM. Future interventions can recruit popular opin-
ion leaders (ie, MSM who have been vaccinated and are
influential among their peers) to promote MenACWY vac-
cination among MSM. Strong recommendations for
MenACWY vaccination by health care providers who
specialize in HIV care are needed routinely and during IMD
outbreaks.
Limitations
Our study had several limitations. First, we excluded MSM
aged <18 and MSM who did not attend LGBTQ-identified
venues, so we cannot generalize our results to MSM who do
not fit these criteria. Second, several sources of bias limited
the ability of self-reported vaccination decisions to represent
actual vaccination behavior, including recall, response, and
social desirability bias. We included only those who
responded yes or no to the question assessing MenACWY
vaccination, thereby excluding those who were unsure about
their vaccination status. Because our study was a rapid
response to the unfolding events of the IMD outbreak, we
could not verify vaccination status through a third party;
therefore, we decided to exclude those who were unsure
about having received the MenACWY vaccine. Future stud-
ies should seek to verify immunization status in collaboration
with health care providers or with data from the California
Immunization Registry. Third, our data were cross-sectional,
and we could not make causal inferences.
Fourth, although we used venue-based sampling, a strat-
egy that would theoretically result in generalizability, this
sample may not be representative of all MSM in Los Angeles
County. For example, although the sample was racially and
ethnically diverse, most respondents were employed,
insured, and well educated, and lived in areas not character-
ized by poverty (ie, in ZIP codes in which 20% of all
families lived below the federal poverty level). When we
compared the racial/ethnic distribution in our sample with
the distribution found in probability samples of MSM in
California (51.6% white, 5.1% black/African American,
35.0% Hispanic, and 8.3% other),51 the distributions were
somewhat similar, except that our sample had fewer non-
Hispanic white men and more non-Hispanic black/African
American men. Although other characteristics of our sample
were somewhat similar to those in probability samples of
MSM in California,51 we cannot generalize our results to all
MSM in California.
Conclusions
Given the heightened risk of IMD during an outbreak that
primarily affected MSM, participants in our sample were not
adequately protected against IMD. Our study offers impor-
tant insights into the correlates of MenACWY vaccine
uptake among MSM in Los Angeles County. Most HIV-
positive MSM who reported receiving the MenACWY
vaccine received 1 dose within the 6 months before partici-
pating in our study questionnaire, suggesting that public health
and community stakeholder efforts influenced uptake during
the outbreak. This result may also demonstrate that the health
advisory issued by the California Department of Public Health
that urged PLWHA to get vaccinated was successful.52
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Research on subgroups of MSM in nontraditional settings
and/or those who are socially or geographically isolated in
Southern California would help to inform vaccination out-
reach campaigns. Incorporating vaccination measures into
population-based research, such as the National Health
Interview Survey and the California Health Interview
Survey, is also warranted to improve immunization sur-
veillance among MSM. Future interventions should focus
on getting HIV-positive men to complete the 2-dose
MenACWY vaccine series. Education efforts targeting HIV
care providers may be useful in reaching HIV-positive
MSM. Greater challenges exist in improving MenACWY
vaccination coverage among HIV-negative MSM during
outbreaks. Vaccination promotion efforts must prioritize
education and use tailored promotion strategies to reach this
population. Failure to address the barriers and challenges
that inhibit MSM from receiving MenACWY vaccine will
likely result in more preventable deaths and lifelong impair-
ments from IMD among MSM.
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